Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID‐A study
Journal of the American Geriatrics Society2021Vol. 69(6), pp. 1441–1447
Citations Over TimeTop 10% of 2021 papers
Sergio Salmerón Ríos, Marta Mas Romero, Elisa Belén Cortés Zamora, María Teresa Tabernero Sahuquillo, Luis Romero Rizos, Pedro Manuel Sánchez‐Jurado, Ginés Sánchez Nievas, José Joaquín Blas Señalada, Inmaculada García Nogueras, Juan de Dios Estrella Cazalla, Fernando Andrés‐Pretel, Antonio Murillo Romero, Volker M. Lauschke, Justin Stebbing, Pedro Abizanda
Abstract
The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.
Related Papers
- → Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study(2017)84 cited
- → Profile of vitamin D in a cohort of physicians and diabetologists in Kolkata(2012)23 cited
- → Aggregation and Immunogenicity of Therapeutic Proteins(2010)38 cited
- → Immunogenicity of Therapeutic Proteins(2010)29 cited
- → Cohort profile: COVID-19 in a cohort of pregnant women and their descendants, the MOACC-19 study(2020)